Troubles mount for Cassava Sciences, as enrollment lags for drug studies – STAT

Biotech & Pharma
Health Tech
Business & Policy
Health & Science
Team
Exclusive analysis of biotech, pharma, and the life sciences
Topics
Columns
Tools
Events
Team
Account
More
Follow Us
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
By Adam Feuerstein April 5, 2022
Cassava Sciences conceded Tuesday that only a relative handful of patients with Alzheimer’s have been enrolled in its late-stage clinical trials — a sign that ongoing investigations over the credibility of its experimental drug simufilam have made physicians and patients wary.
On a company-sponsored webcast, Cassava CEO Remi Barbier said 60 patients have begun treatment across its two Phase 3 clinical trials. The studies, which randomize patients to receive either simufilam or a placebo, have been expected to enroll 1,750 patients.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
Senior Writer, Biotech
Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast.



This name will appear with your comment
There was an error saving your display name. Please check and try again.
By Adam Feuerstein
By Adam Feuerstein
advertisement
By Adam Feuerstein
By Lev Facher
By Adam Feuerstein and Nicholas Florko
Reporting from the frontiers of health and medicine

source

Add a Comment

Your email address will not be published. Required fields are marked *